Cancer vaccines as promising immuno-therapeutics: platforms and current progress

被引:443
作者
Liu, Jian [1 ]
Fu, Minyang [1 ]
Wang, Manni [1 ]
Wan, Dandan [1 ]
Wei, Yuquan [1 ]
Wei, Xiawei [1 ]
机构
[1] Sichuan Univ, Lab Aging Res & Canc Drug Target, State Key Lab Biotherapy, West China Hosp,Natl Clin Res Ctr Geriatr, 17,Block 3,Southern Renmin Rd, Chengdu 610041, Sichuan, Peoples R China
基金
美国国家科学基金会;
关键词
Cancer vaccine; Tumor antigens; Tumor resistance; Immunotherapy; Clinical application; DENDRITIC CELL VACCINE; T-CELLS; DNA VACCINE; TUMOR-ANTIGENS; LIPID NANOPARTICLES; NEOANTIGEN VACCINE; ONCOLYTIC VIRUSES; MELANOMA PATIENTS; NY-ESO-1; PROTEIN; CLINICAL-TRIAL;
D O I
10.1186/s13045-022-01247-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Research on tumor immunotherapy has made tremendous progress in the past decades, with numerous studies entering the clinical evaluation. The cancer vaccine is considered a promising therapeutic strategy in the immunotherapy of solid tumors. Cancer vaccine stimulates anti-tumor immunity with tumor antigens, which could be delivered in the form of whole cells, peptides, nucleic acids, etc. Ideal cancer vaccines could overcome the immune suppression in tumors and induce both humoral immunity and cellular immunity. In this review, we introduced the working mechanism of cancer vaccines and summarized four platforms for cancer vaccine development. We also highlighted the clinical research progress of the cancer vaccines, especially focusing on their clinical application and therapeutic efficacy, which might hopefully facilitate the future design of the cancer vaccine.
引用
收藏
页数:26
相关论文
共 236 条
[1]   Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant [J].
Adams, Sylvia ;
O'Neill, David W. ;
Nonaka, Daisuke ;
Hardin, Elizabeth ;
Chiriboga, Luis ;
Siu, Kimberly ;
Cruz, Crystal M. ;
Angiulli, Angelica ;
Angiulli, Francesca ;
Ritter, Erika ;
Holman, Rose Marie ;
Shapiro, Richard L. ;
Berman, Russell S. ;
Berner, Natalie ;
Shao, Yongzhao ;
Manches, Olivier ;
Pan, Linda ;
Venhaus, Ralph R. ;
Hoffman, Eric W. ;
Jungbluth, Achim ;
Gnjatic, Sacha ;
Old, Lloyd ;
Pavlick, Anna C. ;
Bhardwaj, Nina .
JOURNAL OF IMMUNOLOGY, 2008, 181 (01) :776-784
[2]   Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 [J].
Alexopoulou, L ;
Holt, AC ;
Medzhitov, R ;
Flavell, RA .
NATURE, 2001, 413 (6857) :732-738
[3]   The problem with neoantigen prediction [J].
不详 .
NATURE BIOTECHNOLOGY, 2017, 35 (02) :97-97
[4]   Acetylation of Cytidine in mRNA Promotes Translation Efficiency [J].
Arango, Daniel ;
Sturgill, David ;
Alhusaini, Najwa ;
Dillman, Allissa A. ;
Sweet, Thomas J. ;
Hanson, Gavin ;
Hosogane, Masaki ;
Sinclair, Wilson R. ;
Nanan, Kyster K. ;
Mandler, Mariana D. ;
Fox, Stephen D. ;
Zengeya, Thomas T. ;
Andresson, Thorkell ;
Meier, Jordan L. ;
Coller, Jeffery ;
Oberdoerffer, Shalini .
CELL, 2018, 175 (07) :1872-+
[5]   HPV vaccination and cancer prevention [J].
Athanasiou, A. ;
Bowden, S. ;
Paraskevaidi, M. ;
Fotopoulou, C. ;
Martin-Hirsch, P. ;
Paraskevaidis, E. ;
Kyrgiou, M. .
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2020, 65 :109-124
[6]   A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients [J].
Bae, J. ;
Prabhala, R. ;
Voskertchian, A. ;
Brown, A. ;
Maguire, C. ;
Richardson, P. ;
Dranoff, G. ;
Anderson, K. C. ;
Munshi, N. C. .
LEUKEMIA, 2015, 29 (01) :218-229
[7]   mRNA therapeutics in cancer immunotherapy [J].
Beck, Jan D. ;
Reidenbach, Daniel ;
Salomon, Nadja ;
Sahin, Ugur ;
Tureci, Ozlem ;
Vormehr, Mathias ;
Kranz, Lena M. .
MOLECULAR CANCER, 2021, 20 (01)
[8]   A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity [J].
Beissert, Tim ;
Perkovic, Mario ;
Vogel, Annette ;
Erbar, Stephanie ;
Walzer, Kerstin C. ;
Hempel, Tina ;
Brill, Silke ;
Haefner, Erik ;
Becker, Rene ;
Tureci, Ozlem ;
Sahin, Ugur .
MOLECULAR THERAPY, 2020, 28 (01) :119-128
[9]   Treatment of genital warts with an immune-response modifier (imiquimod) [J].
Beutner, KR ;
Spruance, SL ;
Hougham, AJ ;
Fox, TL ;
Owens, ML ;
Douglas, JM .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1998, 38 (02) :230-239
[10]   Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation [J].
Bijker, Martijn S. ;
van den Eeden, Susan J. E. ;
Franken, Kees L. ;
Melief, Cornelis J. M. ;
van der Burg, Sjoerd H. ;
Offringa, Rienk .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2008, 38 (04) :1033-1042